Ann: Changes to Board, page-5

The company needs a positive announcement to balance all the recent negatives:

	Positive	Negative
1	New CEO prepared to provide active direction	MS – gone
2	Glaucoma still in play	Alzheimers – gone
3		Neuroscience specialist director Dr Linda Friedland – gone
4		New board member Chris Ntoumenopoulos – corporate / capital advisory specialist
5		New board member Clarke Barlow – financial services / capital / M&A background

It looks to me like the company's new focus will be on selling the business rather than developing a treatment. I suspect it looked like that to Dr Friedland too.